Salim Syed
Stock Analyst at Mizuho
(1.88)
# 2,961
Out of 4,829 analysts
78
Total ratings
35.48%
Success rate
-9.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $118.17 | +43.01% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $265.86 | +5.32% | 8 | May 7, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $6.59 | +234.09% | 5 | Nov 21, 2024 | |
| NKTX Nkarta | Maintains: Outperform | $20 → $16 | $1.93 | +729.02% | 7 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $90 → $100 | $96.91 | +3.19% | 6 | Nov 21, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $99 → $103 | $31.70 | +224.97% | 6 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $31.16 | +423.11% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $7.31 | +146.24% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $18.42 | +84.58% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $35.62 | +177.93% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $34.17 | +55.11% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.91 | +556.38% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.97 | +2,067.85% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $12.24 | +194.12% | 1 | Nov 16, 2022 |
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $118.17
Upside: +43.01%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $265.86
Upside: +5.32%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $6.59
Upside: +234.09%
Nkarta
Nov 21, 2024
Maintains: Outperform
Price Target: $20 → $16
Current: $1.93
Upside: +729.02%
Gilead Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $90 → $100
Current: $96.91
Upside: +3.19%
Cytokinetics
Nov 21, 2024
Maintains: Outperform
Price Target: $99 → $103
Current: $31.70
Upside: +224.97%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $31.16
Upside: +423.11%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $7.31
Upside: +146.24%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $18.42
Upside: +84.58%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $35.62
Upside: +177.93%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $34.17
Upside: +55.11%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.91
Upside: +556.38%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.97
Upside: +2,067.85%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $12.24
Upside: +194.12%